eTheRNA

eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service

NIEL, BELGIUM, March 28, 2022, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.

eTheRNA Announces Research Agreement With Merck KGaA, Darmstadt, Germany to Access mRNA Technologies

NIEL, Belgium, Feb. 3, 2022 /PRNewswire/ -- eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA,...
Discovery Facitlity — Frieda Saeystraat 1B, 3rd floor, 9052 Zwijnaarde - Gent, Belgium

+32 3 369 17 40